- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library
 |
 |
soluble vascular endothelial growth factor receptor-1 (sFlt-1) antibody and antigen (Recombinant protein)
Diagnostic soluble vascular endothelial growth factor receptor-1 (sFlt-1) antibodies (anti-soluble vascular endothelial growth factor receptor-1, anti-sFlt-1) and antigens (recombinant soluble vascular endothelial growth factor receptor-1 (sFlt-1) protein) for Cancer sFlt-1 detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.
Go to
Neurodegenerative diseases diagnostics
products collection
>>
Product information
| Catalog No. | Description | US $ Price (per mg) |
|---|---|---|
| GMP-h-sFlt-1-Ag01 | Recombinant human FLT1/ FSD2/sFlt-1/FLT/ SPRYD1/FRT Protein | 3090 |
| GMP-h-sFlt-1-Ab01 | Anti-human FLT1/ FSD2/sFlt-1/FLT/ SPRYD1/FRT mouse monoclonal antibody (mAb) | 1953 |
| GMP-h-sFlt-1-Ab02 | Anti-human FLT1/ FSD2/sFlt-1/FLT/ SPRYD1/FRT mouse monoclonal antibody (mAb) | 1953 |
| GMP-h-sFlt-1-Ab03 | Anti-human FLT1/ FSD2/sFlt-1/FLT/ SPRYD1/FRT human monoclonal antibody (mAb) | 1953 |
| GMP-h-sFlt-1-Ab04 | Anti-human FLT1/ FSD2/sFlt-1/FLT/ SPRYD1/FRT human monoclonal antibody (mAb) | 1953 |
Size： 1mg | 10mg | 100mg
Product Description
| Cat No. of Products | GMP-h-sFlt-1-Ag01 |
| Product Name | Recombinant human FLT1/ FSD2/sFlt-1/FLT/ SPRYD1/FRT Protein |
| Target/Biomarker | soluble vascular endothelial growth factor receptor-1(sFlt-1) |
| Alias of Target/Biomarker | FLT, FLT-1, VEGFR-1, VEGFR1, SPRYD1 |
| Expression platform | mammalian |
| Isotypes | Recombinant Antigen |
| Bioactivity validation | soluble vascular endothelial growth factor receptor-1 (sFlt-1) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in sFlt-1 level test of Cancer (ascular diseases and cancer) and related syndrome evaluation. |
| Products description | Recombinant human FLT1/ FSD2/sFlt-1/FLT/ SPRYD1/FRT Protein was expressed in mammalian expression system and is expressed with 6 HIS tag at the C-terminus. |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT. |
| Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
| Cat No. of Products | GMP-h-sFlt-1-Ab01, GMP-h-sFlt-1-Ab02 |
| Product Name | Anti-human FLT1/ FSD2/sFlt-1/FLT/ SPRYD1/FRT mouse monoclonal antibody (mAb) |
| Target/Biomarker | soluble vascular endothelial growth factor receptor-1(sFlt-1) |
| Alias of Target/Biomarker | FLT, FLT-1, VEGFR-1, VEGFR1, SPRYD1 |
| Expression platform | CHO |
| Isotypes | Mouse IgG |
| Bioactivity validation | Human soluble vascular endothelial growth factor receptor-1 (sFlt-1) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other soluble vascular endothelial growth factor receptor-1 (sFlt-1) antibodies in sFlt-1 level test of Cancer (ascular diseases and cancer) and related syndrome evaluation. |
| Tag | mFc |
| Products description | Anti-human FLT1/ FSD2/sFlt-1/FLT/ SPRYD1/FRT mouse monoclonal antibody (mAb) is a monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. |
| Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
| Cat No. of Products | GMP-h-sFlt-1-Ab03, GMP-h-sFlt-1-Ab04 |
| Product Name | Anti-human FLT1/ FSD2/sFlt-1/FLT/ SPRYD1/FRT human monoclonal antibody (mAb) |
| Target/Biomarker | soluble vascular endothelial growth factor receptor-1(sFlt-1) |
| Alias of Target/Biomarker | FLT, FLT-1, VEGFR-1, VEGFR1, SPRYD1 |
| Expression platform | CHO |
| Isotypes | Human lgG1 |
| Bioactivity validation | Human soluble vascular endothelial growth factor receptor-1 (sFlt-1) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other soluble vascular endothelial growth factor receptor-1 (sFlt-1) antibodies in sFlt-1 level test of Cancer (ascular diseases and cancer) and related syndrome evaluation. |
| Tag | hFc |
| Products description | Anti-human FLT1/ FSD2/sFlt-1/FLT/ SPRYD1/FRT human monoclonal antibody (mAb) is a monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. |
| Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker information
Formation of new capillary blood vessels from existing microvessels is called Angiogenesis, which plays a fundamental role in many physiological and pathological processes such as embryo genesis, wound healing and cancer. Angiogenic processes are controlled by a multitude of positive and negative regulators. Vascular endothelial growth factor (VEGF) strongly promotes angiogenesis. VEGF exerts multiple reactions by activating cell membrane receptors with tyrosine kinase activity, such as VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 (Flt-4) (4). The soluble form of the FLT-1 receptor, sFLT-1, is one of the efficient inhibitors of angiogenesis (10,12). The sFLT-1 inhibits VEGF-driven migration of cancer cells. ?VEGF or sFLT-1 genes or their products have been involved in the therapy of vascular diseases and cancer.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.
Facebook
LinkedIn
Twitter
Comments